Country: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
theophylline, anhydrous (UNII: 0I55128JYK) (theophylline - UNII:C137DTR5RG)
Monarch Pharmaceuticals, Inc.
Theophyllin, anhydrous
TABLET
300 mg
ORAL
PRESCRIPTION DRUG
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. QUIBRON® -T ACCUDOSE® Tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
Quibron® -T Tablets: Bottles of 100, ivory, in the ACCUDOSE® Tablet design with “M 020” debossed on one side, containing 300 mg of anhydrous theophylline. NDC 61570-020-01 Store from 15°-25°C (59°-77°F) Rx only. Manufactured for Monarch Pharmaceuticals® , Inc., Bristol, TN 37620 Manufactured by Bristol-Myers Squibb, Princeton, NJ 08543
QUIBRON-T- THEOPHYLLIN, ANHYDROUS TABLET MONARCH PHARMACEUTICALS, INC. ---------- QUIBRON -T (THEOPHYLLINE TABLETS USP) ACCUDOSE TABLETS IMMEDIATE-RELEASE BRONCHODILATOR DES CRIPTION Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1HPurine- 2,6-dione, 3,7- dihydro-1,3-dimethyl-, and is represented by the following structural formula: The molecular formula of anhydrous theophylline is C H N O with a molecular weight of 180.17. Quibron -T is available as tablets intended for oral administration, containing 300 mg of anhydrous theophylline per tablet. Quibron -T is an oral bronchodilator in an immediate-release formulation in the ACCUDOSE Tablet design. With functional trisects and bisects, Quibron -T Tablets can be accurately divided into 100-, 150-, and 200-mg segments to provide a variety of dosing increments, as required. QUIBRON -T TABLETS One-third tablet = 100 mg One-half tablet = 150 mg Two-thirds tablet = 200 mg One tablet = 300 mg INACTIVE INGREDIENTS: microcrystalline cellulose, yellow ferric oxide, hydroxypropyl methylcellulose 2910, lactose monohydrate, magnesium stearate, colloidal silicon dioxide, and sodium starch glycolate. CLINICAL PHARMACOLOGY MECHANISM OF ACTION: Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects assoc সম্পূর্ণ নথি পড়ুন